Key Takeaways
- • Blackstone and TPG are seeking over $4 billion for Hologic's surgical unit, representing a significant portfolio optimization move less than six months after completing their $18.3 billion take-private acquisition of the medical technology company in January 2026.
- • The sale proceeds will be deployed to pay down debt accumulated during the leveraged buyout, a standard deleveraging strategy for large PE acquisitions in the healthcare technology sector.
- • The surgical division represents a material but non-core asset within Hologic's broader portfolio, which includes diagnostics and breast health businesses that were the primary drivers of the PE consortium's acquisition thesis.
- • The transaction signals confidence in Hologic's cash generation capabilities, allowing the sponsors to monetize non-essential assets while maintaining control of higher-margin core operations focused on steady recurring revenue streams.
Summary
Blackstone and TPG are actively exploring the sale of Hologic's surgical division in a transaction that could value the business unit at more than $4 billion, according to reporting by the Financial Times on July 9, 2026. The move comes less than six months after the two private equity firms completed their joint acquisition of Hologic in a transaction valued at up to $79 per share, establishing the medical technology company as a private enterprise following its public market exit.
The surgical unit divestiture is a classic post-acquisition optimization strategy designed to reduce the debt burden incurred during the leveraged buyout. By monetizing the surgical division—a logical candidate for separation given its distinct operational profile—Blackstone and TPG can redeploy proceeds toward debt repayment while retaining Hologic's core diagnostics and breast health businesses, which generate more stable cash flows and aligned better with the original acquisition thesis.
The timing reflects the PE sponsors' assessment that public markets had undervalued Hologic's steady cash generation from its core diagnostics and women's health platforms following the decline in COVID-19 testing demand. Rather than attempting a wholesale operational transformation, the take-private was positioned as a "stabilize and scale" strategy. The surgical unit sale demonstrates that the sponsors have already identified opportunities to optimize the capital structure and unlock value through portfolio rationalization—a key lever in PE value creation playbooks.
Hologic's financial performance supports the sponsors' confidence in the business's durability. Recent quarterly results showed revenue of $1,047.8 million with 2.5% reported growth and 2.9% organic growth excluding COVID-19-related revenues and divested operations. This steady operational performance provides the cash flow foundation necessary to support the debt reduction strategy while the portfolio is refined under private ownership.
The transaction remains exploratory, but a successful $4 billion-plus sale would represent a substantial early-stage capital return for the Blackstone and TPG funds, demonstrating the value creation potential of the original acquisition thesis and providing dry powder for reinvestment or distribution to limited partners.
The surgical unit divestiture is a classic post-acquisition optimization strategy designed to reduce the debt burden incurred during the leveraged buyout. By monetizing the surgical division—a logical candidate for separation given its distinct operational profile—Blackstone and TPG can redeploy proceeds toward debt repayment while retaining Hologic's core diagnostics and breast health businesses, which generate more stable cash flows and aligned better with the original acquisition thesis.
The timing reflects the PE sponsors' assessment that public markets had undervalued Hologic's steady cash generation from its core diagnostics and women's health platforms following the decline in COVID-19 testing demand. Rather than attempting a wholesale operational transformation, the take-private was positioned as a "stabilize and scale" strategy. The surgical unit sale demonstrates that the sponsors have already identified opportunities to optimize the capital structure and unlock value through portfolio rationalization—a key lever in PE value creation playbooks.
Hologic's financial performance supports the sponsors' confidence in the business's durability. Recent quarterly results showed revenue of $1,047.8 million with 2.5% reported growth and 2.9% organic growth excluding COVID-19-related revenues and divested operations. This steady operational performance provides the cash flow foundation necessary to support the debt reduction strategy while the portfolio is refined under private ownership.
The transaction remains exploratory, but a successful $4 billion-plus sale would represent a substantial early-stage capital return for the Blackstone and TPG funds, demonstrating the value creation potential of the original acquisition thesis and providing dry powder for reinvestment or distribution to limited partners.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.